Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, reviews the role of FLT3 inhibitors for treating patients with FLT3-mutated acute myeloid leukemia. Dr Perl discusses how FLT3 inhibitors should be incorporated into treatment regimens for patients receiving lower-intensity therapy.
Rebecca L. Olin, MD, MSCE, associate professor in the Department of Medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses changes in…
Sergio Rutella, MD, PhD, FRCPath, hematologist and professor of cancer immunotherapy at the John van Geest Cancer Research Centre, reports new findings from his work on acute myeloid…
Naval G. Daver, MD, a professor and director of the Leukemia Research Alliance Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses the significant advancements…
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, discusses a study evaluating the efficacy of combining venetoclax with hypomethylating agents in treating patients with acute myeloid leukemia…
Courtney D. DiNardo, MD, clinical researcher in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses how potential doublet…
In the video, Shelley, a 70-year-old diagnosed with acute myeloid leukemia after her chronic myelomonocytic leukemia progressed, shares her cancer journey and how participating in a clinical trial…
In this expert interview, Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses donor selection for allogeneic stem cell transplantation in secondary acute myeloid leukemia (AML) patients…
